Advertiser, covering sustainability issues, alternative energy and weather. She was previously arts page editor, a features ...

The FDA is meeting later this week to decide which variant the 2026-27 COVID vaccine will target. The WHO recommended ...

Gen. Colin Powell, former secretary of state, died Monday at 84 from COVID-related complications, though he was fully ...

COVID-19 but no longer require specialized care. 113 contracted COVID-19 while in hospital. 11 (11.7 per cent) people have had a third dose of COVID-19 vaccine. 60 (63.8 per cent) are fully vaccinated ...

China said it would bolster vaccination among its senior citizens, a move regarded by health experts as crucial to reopening ...

A new variant of the novel coronavirus called EG.5 is spreading in Japan, with experts expecting it to be the dominant strain ...

Moderna (MRNA) stock surged on renewed Hantavirus vaccine interest following a cruise ship outbreak, with Q1 revenue beating consensus at $389M versus $236M expected, driven by $311M in international ...

Pfizer CEO Albert Bourla addressed any doubts about the drugmaker's commitment to its dividend in the Q1 call, stating, "We intend to maintain and over time, grow our dividend as we continue to ...

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for drugmaker Pfizer PFE-0.19%decrease; red down pointing triangle. Pfizer also reaffirmed its sales ...

Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID portfolio grew 9% operationally, led by Abrysvo (+136%) and Lorbrena (+45%), plus a ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, eleventh-hour settlements with two of the three generic drugmakers involved ...